CANCER AND LEUKEMIA GROUP B

加州圣地亚哥大学的调查人员 医学和附属机构计划继续积极， 癌症和白血病组B（CALGB）的多学科成员。 我们 目的是（1）增加集团研究的应计费用（预计总数为 110-125例/年），（2）参与指导知识分子 集团的生产力（通过刺激更多的基础研究组成部分， 临床试验，设计和主持方案，介绍试点 观察组验证和扩展），3）增加参与 小组行政活动（接受任命为委员会成员 主席、核心委员会成员、礼宾主席）（4）提供直接服务 （通过维持有效的细胞表面标记参考） 具有极高的技术质量和科学 完善和作为机构基础， 作为一个整体的CALGB的微型计算机应用），和（5）作为一个 CCOP活动的临床资源和多学科研究基地 （这将进一步加强对CALGB路径的应计）。 继续 参与CALGB将显著提高整体质量， 在整个圣地亚哥地区提供肿瘤护理，并作为一个 重要的教育工具，为教师，研究员，内务人员和学生 在UCSD和附属参与者。 工作人员和受训人员更多地参与CALGB活动， 扩大患者基础（在圣地亚哥退伍军人医疗中心，海军地区 医疗中心，在私人圣地亚哥肿瘤社区，并在我们的 位于拉斯维加斯，内华达州的CCOP附属机构），所有合格患者均入选 适当的CALGB试验（通过增加数据 管理/秘书服务）应允许实现权责发生制 目标. 增加医生参加CALGB国家会议的人数 加州大学圣地亚哥分校的工作人员应该导致新的委员会任命，协议 发展机会，并扩大了我们的智力投入， 机构。 UCSD癌症中心的基础科学资源将是 可为新的试验提供实验室研究组件。 的 细胞表面标志物参考实验室可以扩大其贡献， 开发了进一步的组协议， 能力的 这一整体参与将有望使两个UCSD 和CALGB为癌症的治疗做出有意义的贡献。

The listed investigators at the University of California San Diego School of Medicine and adjunct institutions plan to continue active, multidisciplinary membership in Cancer and Leukemia Group B (CALGB). We aim to (1) increase accrual to Group studies (to a projected total of 110-125 patients/year), (2) participate in directing intellectual productivity of the Group (by stimulating more basic research components to clinical trials, designing and chairing protocol, presenting pilot observation for Group validation and expansion), 3) increase involvement in Group administrative activities (by accepting appointments as committee chairs, core committee members, protocol chairs) (4) provide direct service to the Group (by maintaining an active Cell Surface Marker Reference Laboratory of exceptionally high technical quality and scientific sophistication and serving as the Institutional base for expanding microcomputer applications for CALGB as a whole), and (5) serve as a clinical resource and multidisciplinary research base for CCOP activities (which will further enhance accrual to CALGB trails). Continued participation in CALGB will measurably improve the overall quality of Oncology care delivered in the entire San Diego area and serve as an important educational vehicle for Faculty, Fellows, Housestaff and students at UCSD and affiliated participants. Increased staff and trainee participation in CALGB activities offer an expanded patient base (at San Diego VA Medical Center, Naval Regional Medical Center, in the private San Diego Oncology Community, and at our CCOP affiliate in Las Vegas, Nevada) and entry of all eligible patients on appropriate CALGB trials (facilitated by increased data management/secretarial services) should permit achievement of accrual goals. Increased participation at CALGB national meetings by physicians and staff from UCSD should lead to new committee appointments, protocol development opportunities, and broadened intellectual input from our institution. The basic science resources of the UCSD Cancer Center will be available to provide laboratory research components for new trials. The Cell Surface Marker Reference Laboratory can expand its contributions as further Group protocols are developed which utilize its sophisticated capabilities. This overall participation will hopefully allow both UCSD and CALGB to make meaningful contributions toward the cure of cancer.